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Extracellular matrix composition in COPD
Raquel Annoni*, Tatiana Lanc¸as*, Ryan Yukimatsu Tanigawa*,
Marcus de Medeiros Matsushita#, Sandra de Morais Fernezlian*, Andreina Bruno",
Luiz Fernando Ferraz da Silva*, Peter J. Roughley+, Salvatore Battaglia1,
Marisa Dolhnikoff*, Pieter S. Hiemstrae, Peter J. Sterk**,
Klaus F. Rabe## and Thais Mauad*
ABSTRACT: Extracellular matrix (ECM) composition has an important role in determining airway
structure. We postulated that ECM lung composition of chronic obstructive pulmonary disease
(COPD) patients differs from that observed in smoking and nonsmoking subjects without airflow
obstruction.
We determined the fractional areas of elastic fibres, type-I, -III and -IV collagen, versican,
decorin, biglycan, lumican, fibronectin and tenascin in different compartments of the large and
small airways and lung parenchyma in 26 COPD patients, 26 smokers without COPD and 16
nonsmoking control subjects.
The fractional area of elastic fibres was higher in non-obstructed smokers than in COPD and
nonsmoking controls, in all lung compartments. Type-I collagen fractional area was lower in the
large and small airways of COPD patients and in the small airways of non-obstructed smokers
than in nonsmokers. Compared with nonsmokers, COPD patients had lower versican fractional
area in the parenchyma, higher fibronectin fractional area in small airways and higher tenascin
fractional area in large and small airways compartments. In COPD patients, significant
correlations were found between elastic fibres and fibronectin and lung function parameters.
Alterations of the major ECM components are widespread in all lung compartments of patients
with COPD and may contribute to persistent airflow obstruction.
KEYWORDS: Chronic obstructive pulmonary disease, cigarette smoking, extracellular matrix,
pathology, respiratory function tests
C
hronic obstructive pulmonary disease
(COPD) is a leading cause of mortality
and morbidity worldwide. Its burden is
still underestimated as COPD is under-diagnosed
and under treated in high- and low-income
countries, mainly in the mild stages of the disease
[1–3]. Smoking is the most important risk factor for
the development of COPD. It has been proposed
that the chronic cigarette-induced inflammation is
associated with the development of structural
changes in the lungs of susceptible smokers, which
contribute to progressive airflow limitation [4, 5].
The major lung extracellular matrix (ECM)
components are collagens, elastic fibres, proteo-
glycans, fibronectin and tenascin [6, 7]. Previous
studies have reported a decrease of elastin [8–10]
and proteoglycans [11] and an increase of total
collagen content in the alveoli of COPD patients
[12]. Few studies have assessed ECM composi-
tion at different levels of the airways and lung
parenchyma [13, 14].
Collagens are the most abundant components of
the lung interstitium and, particularly the fibrillar
type-I and -III collagens, are important in main-
taining the lung architecture. Type-IV collagen is
the main constituent of basement membranes
and the most abundant non-fibrillar collagen in
the lungs [15, 16].
Proteoglycans are macromolecules composed of a
protein core and glycosaminoglycan side chains
that are involved in maintaining the assembly of
collagen fibrils, water balance and cell adhesion
and migration [17, 18]. Little is known about the
pattern of proteoglycans deposition in the lungs
of COPD patients. So far, studies described
alterations of versican and decorin in the distal
lung [10, 11].
Tenascin and fibronectin are altered in ongoing
tissue injury, regulating important cell properties
and inflammatory cell chemotaxis [19]. There are
few studies analysing the expression of tenascin
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and fibronectin in COPD patients [13, 20, 21], but no study has
addressed these proteins in all lung compartments.
We hypothesised that the composition of ECM is different in
the large airways, small airways and lung parenchyma and
between patients with COPD and smokers and nonsmokers
with normal lung function. Furthermore, we hypothesised that
such differences contribute to lung function impairment
in COPD.
Therefore, our aim was to quantify the composition of several
ECM components (elastic fibres, type-I, -III and -IV collagen,
versican, decorin, biglycan, lumican, fibronectin and tenascin)
in all lung compartments of patients with COPD, in relation to
cigarette smoking and lung function.
METHODS
This study was approved by the review board of the Sa˜o Paulo
University Medical School and A.C. Camargo Hospital (both
Sa˜o Paulo, Brazil), Leiden University Medical Centre (Leiden,
the Netherlands) and Palermo University (Palermo, Italy). All
subjects provided written informed consent.
Subjects
We analysed lung tissue collected from 68 patients undergoing
lung resection surgery for primary or metastatic lung tumours
from 2001 to 2007.
Information including demographic data, medical and smok-
ing history, medications and pre-operative lung function was
obtained from the patients’ hospital charts. Patients with a
diagnosis of asthma, bronchiectasis, infectious diseases, a1-
antitrypsin deficiency or interstitial lung disease were not
included.
Patients were classified as follows. 1) Nonsmokers (NS, n516);
never-smokers, forced expiratory volume in 1 s (FEV1) o80%
predicted and FEV1/forced vital capacity (FVC)o70%. 2) Non-
obstructed smokers (NOS, n526): current and/or ex-smokers
(quit for o1 month) with normal lung function (FEV1 o80%
pred and FEV1/FVC o70%). 3) COPD (n526): current and/or
ex-smokers (quit for o1 month) with COPD (FEV1/FVC
,70%). Post-bronchodilator values were available in 15 COPD
patients (five Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage I, mild, nine GOLD stage II, moderate,
and one GOLD stage III, severe, [1]), and all showed ,12%
improvement compared with the pre-bronchodilator value.
Tissue processing
Two to four blocks of peripheral parenchyma and one or two
blocks of central airways remote from the tumour were
obtained in most cases. In general, less tissue was available
from central areas because of tumour proximity or surgical
borders. Fragments were fixed in 10% buffered formalin for
24 h, processed and paraffin embedded. 4-mm thick sections
were stained with haematoxylin–eosin for initial analysis. We
excluded cases showing fibrotic disorders, neoplastic tissue
and post-stenotic pneumonia.
Histochemistry
For identification of elastic fibres, the Weigert’s Resorcin–
Fuchsin technique with oxidation was used [22].
Immunohistochemistry
Antigen retrieval and primary antibodies are shown in table 1S
in the online supplementary material. Details of the immuno-
histochemical techniques are described in the online supple-
mentary material.
Morphological analysis
Two large (epithelial basement membrane perimeter .6 mm)
airways and three small (f6 mm) airways cut in a transverse
section, and 10 peribronchiolar (the site of alveolar attach-
ments) and 10 distal alveolar segments (alveolar septa
positioned at least 16100 field from any small airway border)
were analysed for all subjects [23].
The airway walls were subdivided into the inner layer,
comprising the region between the epithelium and the internal
smooth muscle border, the smooth muscle layer and the outer
layer, located between the external smooth muscle border and
the external limit of the airway, i.e. the alveolar parenchyma
(fig. 1S in the online supplementary material).
In large airways, type-IV collagen and tenascin mainly stained
the subepithelial region of the bronchial epithelial layer and
the walls of blood vessels. To avoid including the type-IV
collagen and tenascin present in blood vessels, we analysed
only subepithelial areas in the large airways. These were
defined as a region of 12 mm below the epithelium. We further
analysed the muscle layer of the large airways, the inner and
muscle layer of small airways and the distal and peribronch-
iolar parenchyma. For the large airways, we measured 10 fields
of the subepithelial area at a magnification of 4006.
Fractional areas of each compartment were determined by
image analysis, using the Image-Pro Plus 4.1 for Windows
software (Media Cybernetics, Silver Spring, MD, USA).
Measurements of positively stained areas were performed as
previously described [24]. Staining intensity was analysed
by mean colour density (weighted mean per biopsy) and
presented as intensity value (white50; black5255). Detailed
information is described in the online supplementary material.
Statistical analysis
Statistical analysis was performed with the SPSS 15.0 software
(SPSS, Chicago, IL, USA). Data are presented as mean¡SD
or median (interquartile range (IQR)), depending on data
distribution. To compare data between NS, NOS and COPD
groups a one-way ANOVA or Kruskal–Wallis test was used, as
appropriate. Bonferroni adjustments were used for multiple
analysis tests. We performed a full-factorial general linear
model to assess the effects of group, sex, age and centre on
the fractional areas of ECM components in different lung
compartments; inner, muscle and outer layer were combined
in large and small airways, and peribronchial/distal paren-
chyma were analysed together. The results of the general linear
models are shown only for ECM components that were
significantly different among groups in the univariate ana-
lyses. The complete data of general linear model analysis are
presented in the online supplementary material [25].
The unpaired t-test or the Mann-Whitney test was used to
compare differences between smokers and ex-smokers. Fractional
areas of ECM components were compared in large versus small
airways and in peribronchial versus distal parenchyma using
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paired t-tests. The association between morphological and clinical
data was performed using Pearson’s or Spearman’s coefficient
tests. A p-value of 0.05 was considered significant.
RESULTS
Subjects
The characteristics of the groups are presented in table 1. The
COPD group was similar to the NOS group with respect to age
and smoking history, but, as expected, had lower lung function
than the other two groups. The mean¡SD of FEV1/FVC was
58.3¡9.8% in the COPD subjects compared with 77.5¡6.5%
and 83.4¡7.6% for the NOS and NS, respectively (pf0.0001).
The FEV1/FVC ratio in the COPD patients was below the
lower limit of normal (69.6¡1.7) [26]. Eight of the subjects with
COPD and none of the subjects in the other two groups were
receiving steroids at the time of surgery.
The NS individuals were significantly younger than NOS and
COPD subjects (pf0.007). There were more females than
males in the NS group.
Morphometry
Between 46–67 (mean 58) large airways and 137–157 small
airways (mean 147) were measured depending on the protein
studied. A total of 578 large airways and 1,465 small airways
were measured. The mean perimeter of large airways of NS,
NOS and COPD patients were 11.8¡4.6 mm, 7.4¡1.5 mm and
11.3¡5.3 mm (p50.39), respectively. For small airways the
perimeter was 1.9¡0.8 mm, 2.1¡1.0 mm and 2.0¡1.4 mm
in the NS, NOS and COPD patients (p50.64), respectively.
The total length of peribronchial parenchyma analysed was
12.8 mm, 12.2 mm and 12.9 mm in the NS, NOS and COPD
patients (p50.363), respectively. For distal parenchyma the
total length in NS, NOS and COPD was 17.4 mm, 15.7 mm and
17.3 mm (p50.084), respectively.
Elastic fibres
The fractional area of elastic fibres was higher in NOS
compared to COPD and NS groups in the inner layer
(p,0.03), muscle layer (p,0.0001) and outer layer (p,0.001)
of the large and small airways, as well as peribronchiolar
(p,0.004) and distal parenchyma (p,0.02). There were no
significant differences between NS and COPD (fig. 1). Data are
presented in table 2.
There was a significant effect of group and centre in the large
airways (p50.051 and p50.017, respectively) and in the small
airways (p50.001 and p50.038, respectively) but not of age
and sex. There were significant effects of group (p50.001) and
sex (p50.012), but not of centre and age in the parenchyma
(table 2S online supplementary material).
Immunohistochemical analysis
Immunoreactivity of ECM proteins showed similar patterns of
staining in the lung tissue of COPD patients, NOS and NS. The
complete immunohistochemical data are presented in table 2.
Type-I collagen
The fractional area of type-I collagen in the inner layer of large
airways and in the inner layer and muscle layer of small
airways was lower in COPD patients when compared with NS
(p50.01, p50.004 and p50.03, respectively). In the outer layer
of small airways, type-I collagen was lower in COPD patients
and in NOS when compared to NS controls (pf0.01) (fig. 2).
There were no significant effects of group, centre, age and sex
on large and small airways when all layers were combined
(table 3S online supplementary material).
Type-III and -IV collagen
There were no differences among COPD, NOS and NS in large
or small airways and peribronchial/distal parenchyma. Results
from the immunohistochemical analyses are described in table 2
and the general linear model is described in tables 4S and 5S in
the online supplementary material.
Versican
Versican fractional area was lower only in the distal
parenchyma of the COPD patients compared with that seen
in NS (p,0.05) (fig. 3). There were no differences among
groups for versican fractional areas in large airways, small
airways and in the peribronchiolar parenchyma.
There were no significant effects of group, centre, age and sex
at a parechymal level (table 6S online supplementary material).
Decorin, biglycan and lumican
There were no differences among COPD, NOS and NS in any
of the large or small airway layers or peribronchial/distal
parenchyma. Results from the immunohistochemical analyses
are described in table 2 and the general linear model is
described in tables 7S, 8S and 9S in the online supplementary
material.
Fibronectin
Higher fibronectin fractional area was observed in the inner
layer, muscle layer and outer layer of small airways of the
COPD group compared with the NS and NOS groups (p,0.02,
p,0.05 and p,0.04, respectively) (fig. 4). In large airways
and lung parenchyma there was no difference in fibronectin
fractional area among groups.
There were no significant effects of group, centre, age and sex on
small airway level (table 10S online supplementary material).
TABLE 1 Characteristics of the study groups
Nonsmokers Non-obstructed
smokers
COPD
Subjects 16 26 26
Age yrs 52¡13# 62¡8 67¡9
Male/female 4/12 19/7 24/2
Non-/ex-/current smoker 16/0/0 0/16/10 0/12/14
Pack-yrs 60¡34 67¡33
FEV1 % pred 108.3¡16.8 97.2¡11.4 65.4¡13.8"
FEV1/FVC % 83.4¡7.6 77.5¡6.5 58.3¡9.8"
Data are presented as n or mean¡SD. COPD: chronic obstructive pulmonary
disease; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC:
forced vital capacity. #: pf0.007, significant difference of nonsmoker controls
compared with the other two groups; ": pf0.0001, significant difference of
COPD compared with other two groups.
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Tenascin
The fractional area of tenascin in the subepithelial area
of large airways and in the inner layer of small airways
was higher in the COPD group when compared with NS
controls (p,0.02 versus p,0.01) (fig. 5). There were no
differences among groups for tenascin fractional areas in
muscle layer of large or small airways, or in the lung
parenchyma.
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FIGURE 1. Elastic fibre fractional areas in a–c) large airways (LA), d–f) small airways (SA) and peribronchiolar parenchyma (PP), and g–i) distal parenchyma (DP) of
nonsmokers (a, d and g), non-obstructed smokers (b, e and h) and chronic obstructive pulmonary disease (COPD) subjects (c, f and i). Scale bars550 mm. j–l) Fractional
areas of elastic fibres in the LA, SA, PP and DP. IL: inner layer; ML: muscle layer; OL: outer layer. Data are presented as mean¡SD. ***: p,0.001; #: p,0.03; ": p,0.0001;
+: p,0.004; 1: p,0.02, in relation to nonsmokers and COPD subjects.
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TABLE 2 Fractional areas# of extracellular matrix components in the airways and parenchyma of nonsmokers (NS), non-
obstructed smokers (NOS) and chronic obstructive pulmonary disease (COPD) patients
Large airways Small airways Peribronchiolar
parenchyma
Distal
parenchyma
p-value+
Inner layer" Muscle layer Outer layer Inner layer Muscle layer Outer layer
Elastic fibres
NS 13.2¡7.8 2.7¡2.3 4.9¡5.3 23.5¡13.7e 5.1¡4.1## 14.1¡11.4"" 10.3¡6.3 11.1¡8.8 f0.042
NOS 25.1¡11.4 11¡5.2 15¡7.8 37.2¡13.9e 18.3¡12.6 30.4¡13.3"" 22.9¡13.9 20.5¡12.4 f0.028
COPD 14.2¡7.8 3.1¡2.5 3.5¡2.6 22.8¡13.7 6.6¡5.7## 18.1¡9.1"" 11¡7.8 7.9¡5.3++ f0.025
p-value1 ,0.0311 ,0.000111 ,0.00111 ,0.0311 ,0.000111 ,0.00111 ,0.00411 ,0.0211
Type-I collagen
NS 14.7¡11.6 9.5 (18) 19¡9.8 25.4¡17.7e 8.6 (14) 34.1¡15.8"" 8¡4.7 6.7¡4.4 f0.05
NOS 7.8¡6.3 2 (7) 11¡7.7 17.4¡12e 4.3 (10) 21.7¡11.6"" 7.1¡6 5.7¡4.6 f0.027
COPD 5.3¡5 1.8 (5) 12.3¡10.4 11¡8.6e 3.7 (7) 17.6¡9.3 5.5¡3.1 4.9¡3.5 0.016
p-value1 0.01ee 0.135 0.135 0.004ee 0.03ee f0.01### 0.311 0.473
Type-III collagen
NS 12.3¡10.8 2.6 (14) 18.7¡14.5 8.6 (13) 1.9 (7) 14.4¡12 0.8 (3) 1 (4) 0.85
NOS 10.9¡9.1 1 (2) 11.9¡13.4 8.6 (20) 2 (3) 9.9¡7.6 0.5 (1) 1.7 (3) 0.91
COPD 13¡15.8 0.8 (12) 13¡18.3 3 (12) 1.3 (6) 10.5¡12.1 0.4 (4) 1.6 (6)++ 0.034
p-value1 0.904 0.678 0.547 0.294 0.710 0.407 0.474 0.782
Type-IV collagen
NS 1.5 (2) 31.6¡20 1 (2) 26.7¡14.6 24.8¡12.8 22.2¡11.9 0.44
NOS 2.3 (4) 27.6¡15.7 1 (2) 20.6¡15.4 22.1¡16 28.7¡15.6 0.46
COPD 2.1 (6) 22.6¡13.6 2.2 (2) 19.8¡15.7 26.7¡13.3 20.6¡10.7 0.34
p-value1 0.597 0.324 0.326 0.36 0.556 0.137
Versican
NS 25.9¡16.9 7.8¡8.6 9.7¡6.8 38.6¡22 17.6¡20.3 25.1¡16"" 23.3¡17.5 22.2¡15.5 0.004
NOS 27¡20.7 14.3¡21.6 21.1¡17.9 36.1¡21.1 13.9¡12.8 26.1¡16.9 17.1¡14.8 13.9¡13.5 0.96
COPD 38.2¡18.3 22.7¡20.6 20.9¡14.4 48.5¡16.7 21.5¡14.1 34.6¡18.2"" 20.8¡13.9 10.9¡8++ f0.026
p-value1 0.154 0.147 0.134 0.094 0.236 0.155 0.467 ,0.05ee
Decorin
NS 11.6¡13.1 7.2¡7.4 19.3¡14.9 15¡14.1 6.6 (10) 17.9¡13.4 0.7 (4) 4.4 (10)++ 0.021
NOS 22.5¡17.3 9.8¡8.3 24.3¡17.3 21.2¡19.1 9 (21) 20.1¡15.1 2.8 (7) 1.6 (3) 0.59
COPD 15.1¡18.2 9¡9.6 18.7¡18.8 22.8¡20.6 7.3 (15) 18.6¡15 1 (3) 1.3 (2) 0.92
p-value1 0.296 0.782 0.674 0.442 0.286 0.882 0.444 0.102
Biglycan
NS 16.6¡18.9 4.7 (14) 18.5¡15.9 17.1¡17.3 7.1 (12) 21.8¡14.3 9.6¡8.4 12.9¡12.3 0.56
NOS 18.3¡15.3 5.7 (8) 16.1¡11.6 17.7¡15.9 5.7 (11) 17.9¡14.7 7¡6.1 7.7¡6.4 0.94
COPD 22.8¡19.5 4.7 (25) 17.9¡16.1 18.6¡20.3 4.9 (15) 14.4¡13.5 10¡12.7 8.7¡7.5 0.94
p-value1 0.659 0.693 0.918 0.965 0.76 0.304 0.590 0.220
Lumican
NS 20.8¡18 14.9¡13.3 30.7¡20.4 20.8¡19.2 5.2 (16) 21.8¡16.4 4 (12) 13.6 (16) 0.56
NOS 31.9¡27.4 16.9¡15 37.5¡26.8 26¡21.2 7.3 (16) 21.9¡17.8"" 4 (7) 6.9 (15) 0.029
COPD 26.1¡19.4 21.2¡17.3 30.2¡20.2 31.2¡22.6 10.1 (20) 25.5¡16.7 4.9 (13) 6.9 (7) 0.97
p-value1 0.475 0.532 0.653 0.338 0.274 0.719 0.870 0.420
Fibronectin
NS 9.0¡6.6 3.2¡3.0 8.4¡5.9 6.6¡5.5 5.3¡5.7 11.1¡8.6 20¡12.1 26.5¡9.9 0.84
NOS 11.4¡10.8 5.6¡7.4 16.3¡16.9 13.4¡12.5 6.1¡7.2 16.6¡12.7 24.8¡18.8 28.1¡16.4 0.96
COPD 18.3¡14.1 9.6¡7.4 17.2¡12.3 24.6¡15.7 11.3¡9.6 26.3¡14.5"" 29.8¡15.2 25.7¡14.8++ ,0.04
p-value1 0.136 0.074 0.284 ,0.02""" ,0.05""" ,0.04""" 0.240 0.862
Tenascin
NS 24.4¡25.8 6.6 (18) 0.45 (2) 15.3¡14.9 3.7 (12) 12.1¡8.2 0.19
NOS 44.9¡31.5 4.6 (13) 13.9 (4) 8.5¡9.5 2.6 (10) 11¡10.7++ f0.006
COPD 56.2¡23.4 8.6 (8) 25.6 (11) 17.8¡16.5 4.9 (10) 10.2¡7.4 0.33
p-value1 ,0.02ee 0.451 ,0.01ee 0.075 0.646 0.853
Data are presented as mean¡SD or median (interquartile range), unless otherwise stated. #: expressed as a percentage of the total area in each compartment; ": type-IV collagen and
tenascin quantification were performed in the subepithelial area of the inner layer; +: comparison between compartments of large airways with their respective compartment in small
airways and between peribronchial and distal parenchyma (the p-value corresponds to the highest value found in the five analyses); 1: comparison among the patient groups; e: small
airways inner layer in relation to large airways inner layer; ##: small airway muscle layer in relation to large airways muscle layer; "": small airways outer layer in relation to large airways
outer layer; ++: peribronchial parenchyma in relation to the distal parenchyma; 11: NOS in relation to NS and COPD; ee: COPD in relation to NS; ###: NS in relation to NOS and COPD;
""": COPD in relation to NS and NOS.
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FIGURE 2. Type-I collagen fractional areas in a–c) large airways (LA), d–f) small airways (SA) and peribronchiolar parenchyma (PP), and g–i) distal parenchyma (DP) of
nonsmokers (a, d and g), non-obstructed smokers (b, e and h) and the chronic obstructive pulmonary disease (COPD) subjects (c, f and i). Scale bars550 mm. j, k) Fractional
areas of type-I collagen in the LA and SA. IL: inner layer; OL: outer layer; ML: muscle layer. Data are presented as mean¡SD or median (interquartile range). #: p50.01 in
relation to nonsmoker controls; ": p50.004 in relation to nonsmokers; +: pf0.01 in relation to non-obstructed smokers and COPD subjects; 1: p50.03 in relation to
nonsmokers.
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There were no significant effects of group, centre, age and sex
on airways levels (table 11S online supplementary material).
Large versus small airways/peribronchial versus distal
parenchyma
Differences between ECM fractional areas in large versus small
airways and peribronchiolar and distal alveolar septa are
presented in table 2.
Mean colour density
The results of mean colour density of ECM proteins were
similar to those shown in the fractional area (data not shown).
Clinical–morphological correlations
Within the COPD group, inverse correlations were found
between FEV1 % pred and elastic fibre fractional area of the
outer layer of large airways (r5 -0.66, p50.009) and the muscle
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FIGURE 3. Versican fractional areas in a–c) large airways, d–f) small airways and peribronchiolar
parenchyma (PP), and g–i) in distal parenchyma (DP) of nonsmokers (a, d and g), non-obstructed
smokers (b, e and h) and the chronic obstructive pulmonary disease (COPD) subjects (c, f and i). Scale
bars550 mm. j) Versican fractional areas in distal parenchyma. IL: inner layer; OL: outer layer; ML:
muscle layer. Data are presented as mean¡SD. *: p,0.05 in relation to nonsmokers.
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layer (r5 -0.48, p50.03) of small airways; and between FEV1/
FVC and fibronectin fractional area in the muscle layer of small
airways (r5 -0.39 p50.05) (fig. 2S online supplementary
material).
When only the NOS group was analysed, age was related to
the elastic fibre fractional area of the outer layer of large
airways (r50.74, p50.038). Inverse correlation was found
between pack-yrs and elastic fibre fractional area of distal
parenchyma (r5 -0.59, p50.026). Inverse correlations were also
seen in fibronectin fractional areas between FEV1 % pred and
the inner layer (r5 -0.50, p50.018) and outer layer (r5 -0.47,
p50.027) of small airways (fig. 3S online supplementary
material). There were no correlations between clinical para-
meters and ECM composition in the NS group.
Within COPD patients, significant correlations were seen in
elastic fibre fractional areas between small airways and lung
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FIGURE 4. Fibronectin fractional areas in a–c) large airways, d–f) small airways (SA) and
peribronchiolar parenchyma (PP), and g–i) distal parenchyma (DP) of nonsmokers (a, d and g), non-
obstructed smokers (b, e and h) and the chronic obstructive pulmonary disease (COPD) subjects (c, f and i).
Scale bars550 mm. j) Fibronectin fractional areas in the inner layer (IL), muscle layer (ML) and outer layer
(OL) of SA. Data are presented as mean¡SD. *: p,0.05; #: p,0.02; ": p,0.04, in relation to nonsmokers
and non-obstructed smokers.
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parenchyma (r50.77, p,0.0001). Positive correlations were
observed in versican fractional areas between small airways
and large airways (r50.61, p,0.02), and between small
airways and lung parenchyma (r50.72, p,0.0001). We also
found significant correlations in fibronectin fractional areas
between small airways and lung parenchyma (r50.72,
p,0.0001). Tenascin fractional areas in large airways corre-
lated positively with the lung parenchyma (r50.61, p,0.02).
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FIGURE 5. Tenascin fractional areas in a–c) large airways (LA), d–f) small airways (SA) and peribronchiolar parenchyma (PP), and g–i) distal parenchyma (DP) of
nonsmokers (a, d and g), non-obstructed smokers (b, e and h) and chronic obstructive pulmonary disease (COPD) subjects (c, f and i). Scale bars550 mm. j, k) Tenascin
fractional areas in the subepithelai region (SubE), and the inner layer (IL) of (LA) and SA. ML: muscle layer. Data are presented as mean¡SD. **: p,0.01; #: p,0.02, in
relation to nonsmokers.
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Current versus ex-smokers
Median (IQR) duration of smoking cessation in ex-smokers
was 6.0 (2.25–10) yrs. There were no significant differences in
ECM composition when current smokers were compared with
ex-smokers, irrespective of obstruction (data not shown).
DISCUSSION
In this study we described changes in the composition of the
ECM in large and small airways and alveolar parenchyma of
patients with COPD compared with smoking or nonsmoking
subjects without airflow obstruction. Higher fractional areas of
elastic fibres were found in NOS compared with COPD
patients and NS subjects. The expression of type-I collagen in
the large and small airways and of versican fractional area in
distal parenchyma was lower in COPD compared with NS.
The fractional areas of the fibronectin and tenascin were higher
in small and large (tenascin) airways of patients with COPD.
These results were not influenced by smoking status or pack-
yrs. Our results indicate that COPD features complex altera-
tions in ECM composition in both large and small airways.
Damage of elastic fibres is a classical concept in the pathophy-
siology of COPD, which may result from the elastase/anti-
elastase imbalance caused by cigarette smoking [27]. BLACK et al.
[14] demonstrated less elastic fibres in the distal lung of COPD
patients compared with smokers. Our findings complement this
study, since we demonstrated lower elastic fibre fractional area in
the large and small airways and in the lung parenchyma of
COPD patients compared with NOS. Unexpectedly, when COPD
patients were compared with NS, no differences were found.
How can we interpret these findings? DESLEE et al. [28]
demonstrated increased elastin gene expression in severe
COPD patients without a significant increase in the elastic
fibres density or in the desmosine content. These authors
suggested that severe COPD patients might have a non-
efficient repair of elastic fibres. Our findings are in line with
these observations, and suggest that smokers without COPD
may be able to increase elastin expression as a response to the
smoke-related injury, whereas such an increase may not occur
in COPD. Interestingly, CANTOR et al. [29] have shown that
3 months of exposure to cigarette in mice causes elastic fibre
proliferation in the airways. Humans have an inability to
adequately synthesise elastin in tissues beyond childhood [30].
We have not assessed the integrity/quality of elastic fibres in
this study, but elastic fibre breakdown occurs both in NOS and
COPD patients [31, 32]. Therefore, it is likely that in smokers
elastic fibres may also not be fully functional.
The current inverse associations between airway elastic fibres
content and FEV1 amongst patients with COPD are in line with
previous data [28]. These data suggest that airflow limitation
and/or airway collapse are less common in patients with the
lowest airway elastic fibres content. One may speculate that
lowered elastic fibres content reduces airway wall compliance
thereby increasing airway wall stiffness, which indeed has
been observed in COPD [33] and even in asthma [34]. Hence, in
the presence of COPD lowered airway elastic fibres content
may even represent a protective mechanism against airflow
limitation. Notably, in a combined analysis of COPD patients
and asymptomatic smokers, airway elastic fibres content have
been reported to be positively associated with spirometric
values [14]. The latter was confirmed by including asympto-
matic smokers in the current analysis (data not shown) and
suggests that loss of airway elastic fibres in absence of COPD
may also be detrimental for lung function, similar to loss of
parenchymal elastic fibres as occurs in emphysema [9].
The results of collagen studies in COPD are conflicting. While
some studies demonstrated increased collagen in alveoli of
COPD patients [12, 35], others showed no difference between
COPD and controls [11]. Few studies have focused on collagen
subtypes in the airways. HOGG et al. [36] demonstrated a decrease
in total collagen in bronchioles of severe COPD associated with a
decrease in type-I/-III collagen ratio. GOSSELINK et al. [37] found a
decreased expression of collagen type-I, a1 (COL1A1) and
collagen type-III, a1 (COL3A1) genes associated with the decline
in FEV1 in lung tissue surrounding the bronchioles and in the
small airways, respectively. They suggested that the thickening
of small airways could not be associated to the expression of
genes related to fibrogenesis.
In this study, we demonstrated less type-I collagen fractional
area in COPD patients. We speculate that the loss of structural
proteins leads to a reduction of stiffness of the airways, making
them more susceptible to external forces applied during normal
expiration, favouring collapse. In addition, we observed lower
type-I collagen content in the outer layer of small airways of NOS
compared with NS. It is possible that type-I collagen structural
alterations at this level contribute to the airway–parenchyma
uncoupling described in smokers without COPD [38].
Versican is an abundant member of the hyalectan family of the
proteoglycans in the lungs [18]. We describe smaller versican
fractional area in the distal parenchyma of COPD patients
compared with NS. Conversely, in mild/moderate COPD
patients, MERRILEES et al. [10] demonstrated an increased
versican staining (by semiquantitative analysis) in alveoli of
COPD patients compared with smoking controls. The reason
for these discrepant results is not clear, but can be associated
with the different methods of analyses used in both studies.
Decorin, biglycan and lumican are small proteoglycans which
interact with fibrillar collagens, participating in the mainte-
nance of the extracellular milieu [39–41]. In vitro studies have
indicated that fibroblasts from COPD patients present abnor-
mal production of proteoglycans and altered expression of the
transforming growth factor (TGF)-b Smad pathway when
exposed to cigarette smoke or different cytokines [42, 43]. In
the present study, no differences were found in decorin,
biglycan and lumican expression in mild/moderate COPD
when compared with NOS and NS controls. VAN STRAATEN
et al. [11] showed that decorin and biglycan staining were
decreased in the peribronchiolar area in severe compared with
mild emphysema patients. Later, NOORDHOEK et al. [44]
demonstrated that decorin production by fibroblast cultures
isolated from lung tissue of patients with severe emphysema is
higher in a basal situation and is more significantly down-
regulated after stimulation with TGF-b than the production by
fibroblasts from patients with mild emphysema. Taken
together with our results, alterations in proteoglycans seem
to be more pronounced in the severe forms of COPD.
Tenascin and fibronectin play important morphoregulatory
roles during lung development. In adult life, both proteins are
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altered after tissue injury and inflammation, regulating cell
adhesion, migration and differentiation [7]. Previous studies
have shown that tenascin expression in large airways was
altered in COPD patients and in smokers [20, 45]. Our data
expand on these observations, showing higher tenascin
expression in large and small airways of COPD patients.
Fibronectin was also higher in COPD patients, mainly at the
small airway level. Interestingly, tenascin and fibronectin
induce matrix metalloproteinase expression and activity [7],
contributing to the perpetuation of tissue injury. The inverse
correlation of fibronectin with lung function in COPD patients
reinforces these suppositions.
Our study has limitations. We lack a severe COPD group,
which would have contributed to a more comprehensive
description of the ECM composition in this disease. Another
limitation was the younger age of the NS group, but
multivariate analyses showed no significant effect of age in
the data. Interestingly, an effect of centre was observed for
several proteins, suggesting that ethnic/environmental factors
might affect ECM composition in the lungs and contribute to
different phenotypes in COPD.
Although pulmonary tissue far from the tumour was analysed,
we cannot exclude that the observed changes in ECM were
affected by malignancy. As all patients had malignancies, it is
unlikely that an interaction would occur only in the COPD
group. Some of the COPD patients did not have lung function
assessed following bronchodilator; however, these older adults
were or had been heavy smokers, and had no history of
asthma, lung fibrosis or bronchiectasis.
Since bronchial biopsies from large airways are being used
for research purposes in COPD [46], an important question is
whether disease patterns are similar in the central versus
distal lung. Similar patterns of ECM remodelling in large
and small airways were observed for elastic fibres, type-I
collagen and tenascin in COPD patients. However, more
significant correlations in the pattern of ECM composition in
COPD patients were found between small airways and
parenchyma.
In summary, we showed that alterations of the major ECM
elements, elastic fibres, collagens, versican, fibronectin and
tenascin, are widespread in all lung compartments of mild/
moderate COPD patients. The altered ECM composition in
COPD is likely to contribute to the persistent tissue injury and
may have a role in the airflow obstruction characteristic of this
disease.
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